Eurofins Advinus is a premier preclinical and early development CRO offering drug discovery, preclinical and development stage contract research services in the areas of discovery services, regulatory Toxicology (Safety Assessment), DMPK, Analytical R&D Services and API CDMO. Eurofins Advinus manufactures drug substances to support Toxicology and early clinical studies.
With over 30 years of GLP compliance and certification, Eurofins Advinus serves diverse industries such as Biotech, Pharmaceutical, Biological, Agrochemical, Nutraceutical and Cosmetic. Eurofins Advinus is the only contract research organization (CRO) in India to have developed data in support of 90+ end-to-end IND enabling packages to be submitted to global regulators such as USFDA, EMA, MHRA, Health Canada and others.
💼 Experience
10 + years of experience in Clinical Research Business Development
Strong exposure to Bioanalytical services, preferably Phase I–III clinical studies
Experience working with international clients is an advantage
🔍 Key Responsibilities
Business development for clinical trials (Phase I, II & III) and BA/BE studies
Sales / BD exposure in Bioanalytical services, especially Phase I studies
Understanding of biomarker bioanalysis as part of clinical programs
Ability to identify the right approach, timing, and stakeholders for standalone clinical bioanalysis and biomarker projects
Established contacts with mid-size pharma, biotech, and startups
Strong knowledge of biomarker pricing and proposal preparation
Excellent communication and stakeholder management skills
🎓 Qualification
Master’s degree in Pharmacy (MBA preferred)
Position: Business Development – Clinical Sample Bioanalysis
Location: Bangalore
📩 Interested candidates may send their CV to:
Sekhar.Sompalli@advinus.eurofinsasia.com
🔁 Feel free to share or refer suitable candidates in your network.
Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories.
Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing.
Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.
